Criteria for Inclusion

© 2021-2024 Marine Pharmacology

PHASE 3

1. Peer-reviewed literature on activity and chemical structure available in databases (Pubmed, Pubchem (CAS number), SciFinder, MarineLit, etc.)

2. Marine organism source

3. The compound must be original MNP or structural derivative of MNP (marine-derived).  If it is possible to trace a direct route from one MNP to a drug, then it will be listed. However, a derivative of a derivative (ie 3rd generation drugs) will not be listed.

4. Molecular target may be characterized or being elucidated

5. Clinical trial information publicly available in USA, Europe, Japan, Australia or China

6. Current clinical trials in North America (USA, Canada), Europe, Japan, Australia or China which are recruiting, active and not recruiting, enrolling by invitation will be shown, while  completed trials will not be included.

7. Disease indications available

8. Development supported by an Institution ( Academia, Biotech, Pharmaceutical company, etc)

© 2021-2024 Marine Pharmacology